Skip to main content

  • Individualizing Dual Antiplatelet Therapy (DAPT) Duration Based on Bleeding Risk, Ischemic Risk, or Both: An Analysis From the DAPT Study

    • Posted: 07/14/2022
    • Author:

      Nino Mihatov, Eric A. Secemsky, Dean J. Kereiakes, P. Gabriel Steg, Donald E. Cutlip, Ajay J. Kirtane, Roxana Mehran, Bokai Zhao, Yang Song, C. Michael Gibson and Robert W. Yeh

    • 2022CRM

    Abstract

    Background

    Guidelines recommend individualization of dual antiplatelet therapy (DAPT) duration. Whether to guide decisions based on bleeding risk, ischemic risk or a combination is not known.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details